Synonym
Nadoxolol hydrochloride; Nadoxolol HCl; LL 1530; LL-1530; LL1530;
IUPAC/Chemical Name
(Z)-N',3-dihydroxy-4-(naphthalen-1-yloxy)butanimidamide hydrochloride
InChi Key
QMIHLTWUCXXBQQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H16N2O3.ClH/c15-14(16-18)8-11(17)9-19-13-7-3-5-10-4-1-2-6-12(10)13;/h1-7,11,17-18H,8-9H2,(H2,15,16);1H
SMILES Code
N/C(CC(O)COC1=C2C=CC=CC2=CC=C1)=N\O.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Biological target:
Nadoxolol HCl is a beta-adrenergic receptor blocker.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
296.75
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
TBD
1: Jaeger A, Kopferschmitt J, Sauder P, Benmatti A, Mantz JM. [Acute nadoxolol poisoning. A multicentric study of 35 cases]. Toxicol Eur Res. 1982 May;4(3):163-6. French. PubMed PMID: 7135390.
2: Bernard P, Bedane C, Catanzano G, Robbe J, Bonnetblanc JM. Acute generalized exanthematic pustulosis. An atypical case due to nadoxolol? Dermatologica. 1991;182(2):115-8. PubMed PMID: 1828772.
3: Misztal G, Gumieniczek A. Chromatographic analysis (TLC) aprindine and nadoxolol in human plasma. Acta Pol Pharm. 1994;51(3):215-8. PubMed PMID: 7872014.
4: Misztal G, Przyborowski L. Determination of nadoxolol in human plasma using reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1994 Oct 14;660(2):409-11. PubMed PMID: 7866535.
5: Jaeger A, Kopferschmitt J, Sauder P, Benmatti A, Mantz JM. [Acute poisoning caused by nadoxolol. Multi-center study of 35 cases]. Nouv Presse Med. 1982 Jun 12;11(28):2151-2. French. PubMed PMID: 7110977.
6: Mussini JM. [Peripheral neuropathy during treatment with nadoxolol]. Presse Med. 1985 Mar 30;14(13):748. French. PubMed PMID: 2986092.
7: Warembourg H, Ducloux G. [Clinical study of a new anti-arrhythmia agent: nadoxolol]. Lille Med. 1976 Apr;21(4 Suppl 2):386-8. French. PubMed PMID: 957857.
8: Kapoor M, Anand N, Koul S, Chimni SS, Manhas KS, Raina C, Parshad R, Taneja SC, Qazi GN. Kinetic resolution of 1-chloro-3-(1-naphthyloxy)-2-propanol, an intermediate in the synthesis of beta-adrenergic receptor blockers. Bioorg Chem. 2003 Jun;31(3):259-69. PubMed PMID: 12818235.
